Form 4: Biostem Technologies Director Reports Stock Transaction
Insider Transaction (Form 4)
Mark A Glickman, a Director of Biostem Technologies, reported multiple transactions in common stock on August 27, 2026.
Summary
- Option exercise/conversion: acquired 7,671 Common Stock on August 27, 2026; holds 7,671 after (Direct).
- Option exercise/conversion: disposed of 7,671 Restricted Stock Units on August 27, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Mark A Glickman — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-27 | Option exercise/conversion | Common Stock | 7,671 | — | — | 7,671 |
| 2026-08-27 | Option exercise/conversion | Restricted Stock Units | 7,671 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-27 | Option exercise/conversion (7,671 shares) |
| 2026-08-27 | Option exercise/conversion (7,671 shares) |
Keywords
insider transaction, Form 4, BSEM, BioStem Technologies, Inc., neutral, Mark A Glickman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.